Mechanistic Basis of Diffuse White Matter Disease and Small Vessel Pathology in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01) | PAR 18 413

Opportunity Information: Apply for PAR 18 413

The grant opportunity titled "Mechanistic Basis of Diffuse White Matter Disease and Small Vessel Pathology in Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R01)" (Funding Opportunity Number PAR 18-413) is a National Institutes of Health (NIH) research project grant designed to fund hypothesis-driven studies that get at the biological "how" and "why" behind vascular-related brain injury that can lead to cognitive decline and dementia. The overall focus is on clarifying the cellular and molecular mechanisms involved in two tightly connected problem areas: diffuse white matter disease and cerebral small vessel disease. Rather than supporting purely descriptive work, the announcement emphasizes mechanistic, hypothesis-testing research aimed at explaining what processes cause these pathologies, how the two conditions influence each other, and how they ultimately contribute to cognitive impairment and dementia within the broader VCID framework.

At its core, the FOA is targeting research that can explain the chain of events from small blood vessel dysfunction to white matter injury and then to measurable impacts on thinking and memory. Diffuse white matter disease refers to widespread damage in the brain's white matter, the communication pathways that connect different brain regions. Small vessel pathology refers to disease processes affecting the brain's small arteries, arterioles, capillaries, and venules. The announcement highlights the need to understand the relationship between these two, because small vessel changes can impair blood flow, blood-brain barrier integrity, oxygen and nutrient delivery, waste clearance, and inflammatory signaling, all of which can create conditions that injure white matter. The grant is meant to support projects that dissect these mechanisms at a fine-grained level, such as identifying relevant cell types and pathways (for example, vascular endothelial cells, pericytes, oligodendrocytes, astrocytes, microglia, and neurons) and explaining how their interactions produce the brain changes seen in VCID.

This opportunity uses the NIH R01 mechanism, which generally supports substantial, multi-year research projects that can include a range of experimental approaches. The activity category is health, and the funding instrument type is a grant under a discretionary opportunity category. The FOA lists an award ceiling of $500,000, indicating the upper limit of support expected under the announcement, though actual awards typically depend on scientific scope, budget justification, and institute-specific funding decisions. The original closing date shown in the source information is March 23, 2018, and the FOA creation date is November 17, 2017, which places this as a specific NIH funding round rather than an open-ended program with no deadlines.

Eligibility is broad and includes many different kinds of institutions and organizations, reflecting NIH's intent to attract a wide pool of expertise across neuroscience, vascular biology, immunology, imaging, and dementia research. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized governments; public housing authorities and Indian housing authorities; nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); and small businesses. In addition, the FOA explicitly calls out other eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). That combination signals an interest in expanding participation and encouraging contributions from institutions serving historically underrepresented communities as well as from international teams that can bring unique cohorts, methods, or disease models.

In practical terms, the FOA is a call for research that moves beyond correlating vascular lesions with cognitive symptoms and instead tests specific, biologically grounded explanations for how diffuse white matter disease and small vessel pathology develop and interact. Successful projects under this kind of announcement would be expected to define clear hypotheses, use rigorous experimental designs, and produce evidence that links molecular and cellular events to tissue-level pathology and, ideally, to functional outcomes relevant to cognition. The emphasis on mechanisms and relationships suggests NIH is looking for studies that can ultimately point toward actionable targets for prevention or therapy, such as pathways driving chronic hypoperfusion, microvascular inflammation, blood-brain barrier breakdown, impaired myelin maintenance, or other processes that plausibly connect vascular dysfunction to degeneration of the brain's white matter networks and the clinical progression toward cognitive impairment and dementia.

The FOA is associated with CFDA numbers 93.853 and 93.866, which correspond to NIH program areas supporting research relevant to neurological disorders, stroke, aging, and related conditions. Overall, this opportunity sits squarely in the VCID research space and is intended to strengthen the mechanistic foundation needed to develop better diagnostics, interventions, and preventative strategies for dementias in which vascular disease and white matter injury play central roles.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Basis of Diffuse White Matter Disease and Small Vessel Pathology in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on 2017-11-17.
• Applicants must submit their applications by 2018-03-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 413

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: